Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes

Chaumont, Hugo; Kaczorowski, Flora; San-Galli, Aurore; Michel, P.P.; Tressières, Benoît; Roze, Emmanuel; Quadrio, Isabelle; Lannuzel, Annie

doi:10.1016/j.neurol.2022.11.002

Cited by 12 publications

(4 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This BBB dysfunction as well as the increased levels of cytokines and chemokines may be implicated in both acute neurologic symptoms as well as in LC. Another study with a small sample size in patients with neuro-COVID has shown an increase in CSF biomarkers of neuroinflammation and neurofilament light chain, indicative of neuronal damage [ 298 ]. In a cross-sectional and long-term longitudinal study with a multiomics approach, the prevailing signs of severe neuro-COVID were the dysfunction of the blood–brain barrier, increased microglia activation biomarkers and a polyclonal B cell response targeting self-antigens and non-self-antigens [ 142 ].…”

Section: Laboratory Findings and Biomarkers In Long Covidmentioning

confidence: 99%

Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges

Tsilingiris

Karampela

Christodoulatos

et al. 2023

IJMS

View full text Add to dashboard Cite

Long COVID (LC) encompasses a constellation of long-term symptoms experienced by at least 10% of people after the initial SARS-CoV-2 infection, and so far it has affected about 65 million people. The etiology of LC remains unclear; however, many pathophysiological pathways may be involved, including viral persistence; a chronic, low-grade inflammatory response; immune dysregulation and a defective immune response; the reactivation of latent viruses; autoimmunity; persistent endothelial dysfunction and coagulopathy; gut dysbiosis; hormonal and metabolic dysregulation; mitochondrial dysfunction; and autonomic nervous system dysfunction. There are no specific tests for the diagnosis of LC, and clinical features including laboratory findings and biomarkers may not specifically relate to LC. Therefore, it is of paramount importance to develop and validate biomarkers that can be employed for the prediction, diagnosis and prognosis of LC and its therapeutic response, although this effort may be hampered by challenges pertaining to the non-specific nature of the majority of clinical manifestations in the LC spectrum, small sample sizes of relevant studies and other methodological issues. Promising candidate biomarkers that are found in some patients are markers of systemic inflammation, including acute phase proteins, cytokines and chemokines; biomarkers reflecting SARS-CoV-2 persistence, the reactivation of herpesviruses and immune dysregulation; biomarkers of endotheliopathy, coagulation and fibrinolysis; microbiota alterations; diverse proteins and metabolites; hormonal and metabolic biomarkers; and cerebrospinal fluid biomarkers. At present, there are only two reviews summarizing relevant biomarkers; however, they do not cover the entire umbrella of current biomarkers, their link to etiopathogenetic mechanisms or the diagnostic work-up in a comprehensive manner. Herein, we aim to appraise and synopsize the available evidence on the typical laboratory manifestations and candidate biomarkers of LC, their classification based on pathogenetic mechanisms and the main LC symptomatology in the frame of the epidemiological and clinical aspects of the syndrome and furthermore assess limitations and challenges as well as potential implications in candidate therapeutic interventions.

show abstract

Section: Laboratory Findings and Biomarkers In Long Covidmentioning

confidence: 99%

Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges

Tsilingiris

Karampela

Christodoulatos

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…Did the CSF test positive for cytokines, chemokines, glial factors, 14-3-3, intrathecal immunoglobulins, neopterin, neurofilament light chain, tau, and Aβ1-42, as previously reported? [ 10 ]…”

mentioning

confidence: 99%

SARS-CoV-2-related polyradiculitis during pregnancy

Finsterer,

Mehri

2024

Indian Journal of Anaesthesia

View full text Add to dashboard Cite

“…To rule out central nervous system (CNS) disease such as infectious or autoimmune encephalitis (AIE), in particular, rhombencephalitis, brainstem Bickerstaff encephalitis, and cerebellitis [ 2 ], it is crucial that each included patient had undergone cerebral MRI with contrast medium and cerebrospinal fluid (CSF) studies. CSF studies should not only include cell count, protein level, glucose level, and oligoclonal bands, but also measurement of intrathecal immunoglobulins, neopterin, neurofilament light chain, tau, antibodies related to AIE and levels of cytokines, chemokines, 14-3-3, and glial factors [ 3 ].…”

mentioning

confidence: 99%

Needle EMG of the vagus-innervated striated larynx muscles cannot indicate laryngeal sensory neuropathy

Finsterer¹

2023

Eur Arch Otorhinolaryngol

View full text Add to dashboard Cite

Cerebrospinal fluid biomarkers in SARS-CoV-2 patients with acute neurological syndromes

Cited by 12 publications

References 55 publications

Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges

Laboratory Findings and Biomarkers in Long COVID: What Do We Know So Far? Insights into Epidemiology, Pathogenesis, Therapeutic Perspectives and Challenges

SARS-CoV-2-related polyradiculitis during pregnancy

Needle EMG of the vagus-innervated striated larynx muscles cannot indicate laryngeal sensory neuropathy

Contact Info

Product

Resources

About